Quetiapine — marketed as Seroquel — is prescribed for sleep more often than for any of the conditions it is actually FDA-approved to treat. It is labeled for schizophrenia, bipolar disorder, and, in combination, major depressive disorder. None of those indications are insomnia. Yet low-dose quetiapine, typically 25 to 100 mg at bedtime, is one of the most common off-label prescriptions in primary care and psychiatry for patients with sleep complaints, particularly patients who are being tapered off benzodiazepines or who have not responded to standard hypnotics.
The drug is an antipsychotic. That framing matters, and it is regularly lost in the prescribing context. A patient who would reasonably decline an antipsychotic for insomnia if it were presented that way accepts quetiapine because it has been presented as a sleep medication.
Why Quetiapine Is Prescribed for Sleep
At low doses, quetiapine’s pharmacology is dominated by histamine H1 receptor antagonism, similar to what is seen with first-generation antihistamines. This produces reliable sedation. Additional activity at 5-HT2A, alpha-1 adrenergic, and muscarinic receptors contributes to the sedating profile at low doses. Dopamine D2 antagonism, the mechanism relevant to the drug’s antipsychotic indications, is modest at 25 to 50 mg and more substantial at higher doses.
From a prescriber’s perspective, quetiapine is attractive for patients with insomnia who have failed other agents, particularly when the clinician wants to avoid controlled substances. It is not a scheduled drug. It does not produce obvious physical dependence of the kind benzodiazepines produce. It is covered by most insurance and available as a generic.
The evidence for quetiapine as a hypnotic is thin. A few small trials show subjective improvement in sleep quality; the data are not adequate to recommend the drug for this indication over better-studied alternatives, and the American Academy of Sleep Medicine’s guidelines do not recommend it. The gap between evidence and prescribing practice is one of the larger ones in psychopharmacology.
What the Side Effect Profile Actually Looks Like
Low-dose quetiapine is often described as benign. Several features of the profile complicate that description.
Metabolic effects. Quetiapine produces weight gain, insulin resistance, and lipid changes at doses well below antipsychotic doses. The weight gain is dose-related but not dose-limited; patients on 25 to 50 mg at bedtime can accumulate 10 to 20 pounds over the first year. Glucose and lipid panels should be monitored in any patient on chronic low-dose quetiapine, and in practice they rarely are.
Orthostatic hypotension. Alpha-1 adrenergic antagonism produces orthostatic effects that are most pronounced early in treatment and in older patients. Nighttime bathroom visits with orthostatic syncope are a recognized cause of falls.
Akathisia. Even at low doses, quetiapine can produce restlessness and an internal sense of agitation. This is often misread as “worsening anxiety” and produces a dose-increase reflex that makes the problem worse.
QT prolongation. Quetiapine prolongs the QT interval in a dose-related way. At low doses the effect is modest, but in combination with other QT-prolonging agents (some antidepressants, ondansetron, methadone) the additive risk matters.
Anticholinergic load. Muscarinic antagonism contributes to dry mouth, constipation, urinary hesitancy, and cognitive symptoms, particularly in older patients. Stacked on other anticholinergics, the total burden is not trivial.
The Withdrawal Question
Quetiapine produces physical dependence and withdrawal on discontinuation, particularly after months of continuous use. The most common withdrawal symptoms are rebound insomnia (often worse than the original complaint), rebound anxiety, nausea, sweating, and in some patients akathisia and dyskinetic movements. Protracted symptoms are less well characterized than with benzodiazepines but are reported.
The rebound insomnia deserves specific attention. Patients who try to discontinue quetiapine abruptly typically experience several nights of nearly no sleep. This is not a return of the original sleep problem — it is a withdrawal phenomenon driven by rebound H1 activity and often accompanies heightened arousal, vivid dreaming when sleep does come, and daytime agitation. The reflexive conclusion is that the patient “needs the medication,” and they resume it. That conclusion is incorrect in most cases; the rebound window usually resolves over one to two weeks on a slow taper.
Quetiapine During a Benzodiazepine Taper
A specific and common clinical pattern: a patient tapering a benzodiazepine develops insomnia. The prescriber adds low-dose quetiapine. The insomnia improves initially. The benzodiazepine taper continues. At some point the patient wants to stop the quetiapine as well. They are now facing a second withdrawal that was created by the management of the first.
This pattern is avoidable if the decision to add quetiapine is made with its exit strategy attached. It is rarely avoided because the exit strategy is rarely defined at the time of the original prescription.
For patients already in this situation, the typical sequence is to complete the benzodiazepine taper first, allow several months of stabilization, and then taper the quetiapine. Tapering both simultaneously multiplies the withdrawal burden in ways most patients cannot sustain.
Deprescribing Quetiapine
The principles are similar to those for benzodiazepines and gabapentin, with quetiapine-specific adjustments.
Slow taper. Reductions of 12.5 to 25 mg every two to four weeks, with smaller reductions as the dose falls below 25 mg, are well tolerated by most patients. For patients on long-term use or with prior failed attempts, slower is better. The Maudsley Deprescribing Guidelines (Horowitz and Taylor, 2024) provide hyperbolic tapering schedules for antipsychotics, including quetiapine, that are applicable here.
Liquid formulation at low doses. Quetiapine is available as a suspension for compounding; small, smooth reductions below 25 mg are not feasible with tablets.
Non-pharmacologic sleep work in parallel. The taper is easier if basic sleep hygiene, stimulus-control therapy, and a stable schedule are in place before the first reduction. Cognitive behavioral therapy for insomnia (CBT-I) is the evidence-based treatment for chronic insomnia and has durable effects that the medications do not produce.
Hold through rebound. A rebound flare during dose reduction is not a signal to restart; it is a signal to hold the dose for another two to four weeks before the next reduction.
What to Ask at the Prescriber Visit
Patients on quetiapine for sleep can reasonably raise several questions: What is the off-label evidence for quetiapine in insomnia? What is the plan for eventual discontinuation? What metabolic monitoring has been done? Are there alternative approaches — CBT-I, sleep restriction therapy — that have not yet been tried?
These are not adversarial questions. They are the questions that ought to be answered at the time a low-dose antipsychotic is being considered for an off-label sleep indication. When they are answered, the prescription is often still appropriate. When they are not answered and the prescription is written anyway, the pattern is the one this post describes.